These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29164292)

  • 1. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.
    Mahé K; Delluc A; Chauveau A; Castellant P; Mottier D; Dalbies F; Berthou C; Guillerm G; Lippert E; Ianotto JC
    Ann Hematol; 2018 Jan; 97(1):101-107. PubMed ID: 29164292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.
    Ianotto JC; Couturier MA; Galinat H; Mottier D; Berthou C; Guillerm G; Lippert E; Delluc A
    Int J Hematol; 2017 Oct; 106(4):517-521. PubMed ID: 28623609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
    Hernández-Boluda JC; Arellano-Rodrigo E; Cervantes F; Alvarez-Larrán A; Gómez M; Barba P; Mata MI; González-Porras JR; Ferrer-Marín F; García-Gutiérrez V; Magro E; Moreno M; Kerguelen A; Pérez-Encinas M; Estrada N; Ayala R; Besses C; Pereira A;
    Ann Hematol; 2015 Jun; 94(6):911-8. PubMed ID: 25680896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists].
    Cambus JP; Magnin D; Ambid-Lacombe C; Bura A; Desgrippes F; Schneller JM; Benhamou Y; Flaujac C; Horellou MH; De Raucourt E; Kaczan D; Astoul JM; Siguret V
    Rev Med Interne; 2013 Sep; 34(9):515-21. PubMed ID: 23523077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
    Wehmeier A; Daum I; Jamin H; Schneider W
    Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
    Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of venous thromboembolism in myeloproliferative neoplasms.
    Barbui T; De Stefano V
    Curr Opin Hematol; 2017 Mar; 24(2):108-114. PubMed ID: 27875375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prescription and follow-up of antithrombotic treatment with vitamin K antagonists].
    Bounhoure JP
    Bull Acad Natl Med; 2013 Nov; 197(8):1561-70; discussion 1570-1. PubMed ID: 26021177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
    Arachchillage DR; Laffan M
    Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patients' knowledge on their vitamin K antagonist treatment.
    Mzoughi K; Zairi I; BenGhorbel F; Ben Kilani M; Kamoun S; Ben Moussa F; Fennira S; Kraiem S
    Tunis Med; 2018 Mar; 96(3):182-186. PubMed ID: 30325485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.
    De Stefano V; Rossi E; Carobbio A; Ghirardi A; Betti S; Finazzi G; Vannucchi AM; Barbui T
    Blood Cancer J; 2018 Nov; 8(11):112. PubMed ID: 30420642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
    Taniguchi Y; Tanaka H; Luis EJ; Sakai K; Kumode T; Sano K; Serizawa K; Rai S; Morita Y; Hanamoto H; Tsubaki K; Nishio K; Matsumura I
    Int J Hematol; 2017 Nov; 106(5):691-703. PubMed ID: 28780601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Educational and information needs of patients under vitamin K antagonist therapy].
    Ben Jeddou K; Ben M'Barka F; Boukhris I; Arfaoui H; Baccar H; Khalfalah N; Ouhachi Z
    Rev Med Interne; 2018 Jul; 39(7):546-550. PubMed ID: 29789192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is the use of vitamin K antagonists harmful in patients with CDK?].
    Pham TT; Saudan P
    Rev Med Suisse; 2012 Feb; 8(330):462-5. PubMed ID: 22452132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey.
    Ellis MH; Lavi N; Vannucchi A; Harrison C
    Thromb Res; 2014 Aug; 134(2):251-4. PubMed ID: 24842684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
    Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
    Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.